An August 2026 FDA-hosted company announcement details Baxter’s voluntary nationwide recall of two lots of 0.9% Sodium Chloride Injection related to possible fiberglass particulate matter in the solution.
FDA-Hosted Notice Details Baxter Sodium Chloride Injection Recall
On August 26, 2026, the FDA published a company announcement detailing Baxter’s voluntary nationwide recall of two lots of 0.9% Sodium Chloride Injection, USP, 500 mL, due to the potential presence of fiberglass particulate matter. The affected lots were distributed to healthcare providers and distributors in 14 states. For Med Spa and wellness practices that provide IV therapy, the recall may apply to on-site inventory and related operations.
Recall Notice Details Distribution and Affected Product Lots
As reported by the FDA on August 26, 2026, Baxter International Inc. initiated a voluntary recall on August 25, 2026. The announcement notes that affected units of the 0.9% Sodium Chloride Injection product can be identified using the lot number and expiration date printed on the individual product and shipping carton. Distribution occurred from July 31 through August 3, 2026, to healthcare providers and distributors in 14 states. The 500 mL VIAFLEX Plastic Containers are packaged in cases of 24 units.
The affected product information includes:
- Product: 0.9% Sodium Chloride Injection, USP, 500 mL VIAFLEX Plastic Container
- Product code: 2B1323Q
- Lot numbers: Y495523 and Y495523A
- Expiration date: October 31, 2027
- NDC: 0338-0049-03
The identified distribution states were:
- Florida
- Illinois
- Indiana
- Louisiana
- Maryland
- Missouri
- North Carolina
- New Jersey
- Nevada
- New York
- Ohio
- South Carolina
- Texas
- Virginia
The recall involves the potential presence of particulate matter identified as fiberglass. In its announcement, the company warns that intravenous administration of a solution containing fiberglass particulate may cause serious adverse health consequences, including vascular blockage or clotting, pulmonary embolism, organ damage, or result in fatality. Other potential effects include local vein irritation, inflammatory reactions, aggravation of preexisting infections, and allergic reactions. As of August 25, 2026, Baxter had received no reports of related adverse events.
Source Attribution
According to the FDA-hosted company announcement published on August 26, 2026, Baxter International Inc. initiated the voluntary recall due to the potential presence of fiberglass particulate matter in two lots of 0.9% Sodium Chloride Injection, USP.
Drug Product Recall Considerations for Med Spa and IV Therapy Practices
Baxter’s voluntary manufacturer recall creates an inventory consideration for healthcare practices, Med Spas, wellness clinics, and other settings that store or administer IV products. Per the FDA announcement, Baxter directed customers to immediately stop using affected units and return them in accordance with their facility’s process.
The announcement notes that Baxter is contacting customers by email with instructions to identify and return affected products. For practices that maintain IV solutions on-site, lot numbers and expiration dates can be compared with the recall notice to identify affected units, while removal and return records can document actions taken in response to the recall. The FDA’s MedWatch Adverse Event Reporting program also accepts reports of adverse reactions or quality problems involving the recalled product.
Broader Oversight Context for IV Therapy, Inventory, and Adverse Events
Separate state actions provide broader context for IV therapy, medication inventory, and adverse-event reporting in Med Spa oversight. A 2026 New York multi-agency inspection operation involving 223 businesses included Med Spa facilities offering intravenous infusions and identified expired and suspected counterfeit products.
Adverse-event reporting is also addressed in state-specific requirements. Under Indiana Senate Bill 282, Med Spas subject to the state’s registration requirements beginning January 1, 2027, must notify the Indiana Medical Licensing Board following a serious adverse event as defined by the law.
These state actions and requirements remain separate from the Baxter recall, but provide additional context for IV therapy, medication inventory, and adverse-event procedures in Med Spa operations.
Baxter directed customers to immediately stop using affected units and return them in accordance with their facility’s process.
Operational Considerations Following the Baxter IV Solution Recall
- Review on-site inventory and related records for the affected product code, lot numbers, and expiration date identified in the recall.
- Discontinue use of affected units, consistent with Baxter’s recall instructions.
- Inform staff and clinical providers about the recall and the affected product identifiers.
- Report adverse reactions or product-quality problems through the FDA’s MedWatch program, when applicable.
- Follow FDA and manufacturer updates related to the recall, as applicable.
What to Watch Next
As of August 25, 2026, Baxter reported that it had received no reports of adverse events associated with the recalled product. Further updates, if issued by Baxter or the FDA, may address the recall status, affected product information, or additional safety information associated with the recalled lots.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “A Baxter International facility in Marion, North Carolina” by Harrison Keely, via Wikimedia Commons, licensed under CC BY 4.0.
